Abstract
Thirty-eight children with metastatic neuroblastoma were given a combination of vincristine sulfate and cyclophosphamide in addition to standard surgical and radiotherapeutic management. The two agents were given intravenously on alternating weeks for 12 weeks or longer. Results were best in eight infants under 1 year, five of whom continued to survive free of disease for 16 months. The overall response rate in patients of all ages was 32% (nine out of 28), and the mean survival was 12 months. The combination of the two agents was effective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
